3.900GBP-1.27%Mkt Cap: 21.86M $P/E: —1d ago
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs …
Industry Peers
Health Information Services$38.07BUSDP/E 44.2
$40.77BUSDP/E 44.6
$11.74BUSDP/E 53.0
$11.05BUSD
$8.71BUSDP/E 38.9
$8.10BUSD
$7.14BUSDP/E 10.8
$4.76BUSDP/E 35.5
$4.62BUSDP/E 30.9
$3.96BUSD
$2.75BUSDP/E 97.7
$1.66BUSDP/E 43.4
$1.50BUSDP/E 36.5
$1.48BUSD
$1.28BUSD
$1.21BUSDP/E 59.0
$1.18BUSD
$870.57MUSD
$834.80MUSDP/E 39.7
$738.82MUSDP/E 74.8
| Headline | Source | Time |
|---|---|---|
This week | ||
Older | ||
SSelectScience | ||
 Renalytix shares fall 25% as revenues miss expectations Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) shares dropped 25% to 4.25p after the company posted first-half revenues of $1.6 million and flagged slower-than-expected progress in rolling out its kidney disease diagnostic test. The company, which develops the FDA-approved and... | ||
TThe Twelfth Magpie | ||